![](https://www.diabetesnews.com/wp-content/uploads/2014/03/heart_attack_640-150x150.jpg)
Jardiance (empagliflozin) has been studied for its use in people with heart failure. A study has found it shows effectiveness in patients with reduced ejection fraction (HFrEF). In heart failure with reduced ejection fraction, the heart muscle does not contract efficiently, and a smaller percentage of blood is pumped out of the heart than usual. Read more